Feasibility And Safety Study Of rhBMP-2/CPM For Hip Fractures

PHASE2CompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions
Fractures
Interventions
DRUG

rhBMP-2/CPM

one time injection of 3-5 mL test article at time of internal fracture fixation

DRUG

rhBMP-2/CPM

one time injection of 3-5 mL test article at time of internal fracture fixation

OTHER

surgical intervention alone

surgical internal fixation of fracture defines the standard of care group

Trial Locations (30)

2170

Pfizer Investigational Site, Liverpool

3004

Pfizer Investigational Site, Melbourne

3050

Pfizer Investigational Site, Parkville

4029

Pfizer Investigational Site, Herston

5000

Pfizer Investigational Site, Adelaide

9002

Pfizer Investigational Site, Oulu

11220

Pfizer Investigational Site, Brooklyn

11373

Pfizer Investigational Site, Elmhurst

13009

Pfizer Investigational Site, Marseille

13353

Pfizer Investigational Site, Berlin

20520

Pfizer Investigational Site, Turku

30033

Pfizer Investigational Site, Decatur

33703

Pfizer Investigational Site, Pinellas Park

33756

Pfizer Investigational Site, Clearwater

48149

Pfizer Investigational Site, Münster

80012

Pfizer Investigational Site, Aurora

94010

Pfizer Investigational Site, Créteil

06520

Pfizer Investigational Site, New Haven

08903

Pfizer Investigational Site, New Brunswick

L157J5

Pfizer Investigational Site, Ajax

N7M 5L9

Pfizer Investigational Site, Chatham

M1E 4B9

Pfizer Investigational Site, Scarborough Village

H4J 1C5

Pfizer Investigational Site, Montreal

H-1081

Pfizer Investigational Site, Budapest

H-4043

Pfizer Investigational Site, Debrecen

NO-5009

Pfizer Investigational Site, Bergen

NO-0407

Pfizer Investigational Site, Oslo

SE-581 85

Pfizer Investigational Site, Link?ping

EH16 4SA

Pfizer Investigational Site, Edinburgh

NR4 7UY

Pfizer Investigational Site, Norwich

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00384358 - Feasibility And Safety Study Of rhBMP-2/CPM For Hip Fractures | Biotech Hunter | Biotech Hunter